<SEC-DOCUMENT>0001140361-24-047701.txt : 20241122
<SEC-HEADER>0001140361-24-047701.hdr.sgml : 20241122
<ACCEPTANCE-DATETIME>20241122210513
ACCESSION NUMBER:		0001140361-24-047701
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20241122
FILED AS OF DATE:		20241122
DATE AS OF CHANGE:		20241122

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Grossman Adam S
		CENTRAL INDEX KEY:			0001542517
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		241491699

	MAIL ADDRESS:	
		STREET 1:		65 COMMERCE WAY
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-11-22</periodOfReport>

    <issuer>
        <issuerCik>0001368514</issuerCik>
        <issuerName>ADMA BIOLOGICS, INC.</issuerName>
        <issuerTradingSymbol>ADMA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001542517</rptOwnerCik>
            <rptOwnerName>Grossman Adam S</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ADMA BIOLOGICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>465 STATE ROUTE 17</rptOwnerStreet2>
            <rptOwnerCity>RAMSEY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07446</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <officerTitle>President and CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-11-22</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>48967</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>21.1</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1989007</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                    <footnoteId id="F5"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1143426</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F6"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>580957</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F7"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">These shares represent restricted stock units (&quot;RSUs&quot;) that were granted on September 29, 2021 and vested on June 30, 2024 and September 30, 2024.</footnote>
        <footnote id="F2">The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.13. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</footnote>
        <footnote id="F3">Includes, as of the transaction date, (i) 557,728 restricted stock units (&quot;RSUs&quot;) granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;</footnote>
        <footnote id="F4">(continued from footnote 3) (iv) 56,719 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;</footnote>
        <footnote id="F5">(continued from footnote 4) and (vi) 748,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.</footnote>
        <footnote id="F6">These shares are owned by Areth, LLC (&quot;Areth&quot;). The reporting person is a control person of Areth.</footnote>
        <footnote id="F7">These shares are owned by Hariden, LLC (&quot;Hariden&quot;). The reporting person is the managing member of Hariden.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact</signatureName>
        <signatureDate>2024-11-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
